- Home
- ACXP vs TOVX Comparison
ACXP vs TOVX Comparison
Compare ACXP & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACXP | TOVX |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 7.2M |
| IPO Year | 2021 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ACXP | TOVX |
|---|---|---|
| Price | $1.97 | $0.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $143.67 | N/A |
| AVG Volume (30 Days) | 41.0K | ★ 2.1M |
| Earning Date | 03-17-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.89 | $0.17 |
| 52 Week High | $21.00 | $1.75 |
Technical Indicators
Market Signals| Indicator | ACXP | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 27.56 | 45.73 |
| Support Level | $1.89 | $0.18 |
| Resistance Level | $2.20 | $0.21 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 5.27 | 33.14 |
Price Performance
Historical ComparisonAbout ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.